Cargando…

Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors

Extracellular acidification is an important feature of tumor microenvironments but has yet to be successfully exploited in cancer therapy. The reversal of the pH gradient across the plasma membrane in cells that regulate intracellular pH (pHi) has potential to drive the selective uptake of weak acid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hay, Michael P., Shin, Hong Nam, Wong, Way Wua, Sahimi, Wan Wan, Vaz, Aaron T.D., Yadav, Pooja, Anderson, Robert F., Hicks, Kevin O., Wilson, William R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680510/ https://www.ncbi.nlm.nih.gov/pubmed/31295864 http://dx.doi.org/10.3390/molecules24142524

Ejemplares similares

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
por: Dickson, Benjamin D., et al.
Publicado: (2019)

Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice
por: Gu, Yongchuan, et al.
Publicado: (2017)

Spin Trapping Hydroxyl and Aryl Radicals of One-Electron Reduced Anticancer Benzotriazine 1,4-Dioxides
por: Qi, Wen, et al.
Publicado: (2022)

The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Regioselective Fluorination of 7-Oxo-1,2,4-benzotriazines Using Selectfluor
por: Mirallai, Styliana I., et al.
Publicado: (2019)

1,2,3-Benzotriazine Synthesis by Heterocyclization of p-Tosylmethyl Isocyanide Derivatives
por: Maqueda-Zelaya, Francisco, et al.
Publicado: (2023)

Design, Synthesis, and Antitumor Activities of Some Novel Substituted 1,2,3-Benzotriazines
por: Lv, Jin-Ling, et al.
Publicado: (2008)

Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents
por: Sorensen, Eric S., et al.
Publicado: (2020)

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
por: Guise, Christopher P., et al.
Publicado: (2014)

Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling
por: Foehrenbacher, Annika, et al.
Publicado: (2013)

Synthesis, Preferentially Hypoxic Apoptosis and Anti-Angiogenic Activity of 3-Amino-1,2,4-Benzotriazine-1,4-Dioxide Bearing Alkyl Linkers with a 3-Amino-1,2,4-Benzotriazine-1-Oxide Moiety
por: Lee, Chun-I, et al.
Publicado: (2014)

Preparation of 3-Substituted Isoindolin-1-one, Cinnoline, and 1,2,4-[e]-Benzotriazine Derivatives
por: El Dhaibi, Fatat B., et al.
Publicado: (2022)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021)

From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates
por: Wang, Yanming, et al.
Publicado: (2022)

Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104
por: Foehrenbacher, Annika, et al.
Publicado: (2013)

Toward Hypoxia-Selective DNA-Alkylating Agents Built by Grafting Nitrogen Mustards onto the Bioreductively Activated, Hypoxia-Selective DNA-Oxidizing Agent 3-Amino-1,2,4-benzotriazine 1,4-Dioxide (Tirapazamine)
por: Johnson, Kevin M., et al.
Publicado: (2014)

Hypoxia-activated prodrugs and redox-responsive nanocarriers
por: Zeng, Yun, et al.
Publicado: (2018)

Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy
por: Denny, William A.
Publicado: (2022)

In vitro radiosensitization of breast cancer with hypoxia‐activated prodrugs
por: Aiyappa‐Maudsley, Radhika, et al.
Publicado: (2022)

Antibody-Based Imaging of Bioreductive Prodrug Release in Hypoxia
por: Tosun, Çağla, et al.
Publicado: (2023)

3-[(R)-1-Hydroxybutan-2-yl]-1,2,3-benzotriazin-4(3H)-one
por: Rocha-Alonzo, Fernando, et al.
Publicado: (2012)

Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures
por: Hong, Cho R., et al.
Publicado: (2018)

Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling
por: Jackson-Patel, Victoria, et al.
Publicado: (2022)

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
por: Phillips, Roger M.
Publicado: (2016)

Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
por: Hunter, Francis W, et al.
Publicado: (2016)

Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma
por: Liu, Shujing, et al.
Publicado: (2017)

The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
por: Nytko, Katarzyna J., et al.
Publicado: (2017)

Hypoxia-Activated Albumin-Binding Exatecan Prodrug for Cancer Therapy
por: Cheng, Zhiyang, et al.
Publicado: (2021)

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect()()
por: Hong, Cho Rong, et al.
Publicado: (2018)

Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy
por: Fuhrmann, Gregor, et al.
Publicado: (2018)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models
por: Liapis, Vasilios, et al.
Publicado: (2016)

Convenient Synthesis of Salicylanilide Sulfonates from 1,2,3-Benzotriazin-4(3H)-ones and Organosulfonic Acids via Denitrogenative Cross-Coupling
por: Korivi, Ramaraju, et al.
Publicado: (2023)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
por: Liapis, Vasilios, et al.
Publicado: (2017)

Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302
por: Wojtkowiak, Jonathan W, et al.
Publicado: (2015)

Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors
por: Lindsay, Danika, et al.
Publicado: (2016)

Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer
por: Shah, Vidhi M., et al.
Publicado: (2022)

Disulfide based prodrugs for cancer therapy
por: Wang, Qiang, et al.
Publicado: (2020)

Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104
por: Benito, Juliana, et al.
Publicado: (2011)

Significance of Specific Oxidoreductases in the Design of Hypoxia-Activated Prodrugs and Fluorescent Turn off–on Probes for Hypoxia Imaging
por: Janczy-Cempa, Ewelina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2umi9cqc5h2vp5v777ftv20c85